Cefpodoxime Dosing
For adults with normal renal function, cefpodoxime should be dosed at 100-200 mg every 12 hours for most infections, with 400 mg every 12 hours reserved for severe infections like pneumonia or skin/soft tissue infections, and treatment duration ranging from 5-14 days depending on the indication 1.
Adult Dosing by Indication
The FDA-approved dosing for adults and adolescents ≥12 years is 1:
- Pharyngitis/tonsillitis: 100 mg every 12 hours for 5-10 days
- Acute community-acquired pneumonia: 200 mg every 12 hours for 14 days
- Acute bacterial exacerbations of chronic bronchitis: 200 mg every 12 hours for 10 days
- Uncomplicated gonorrhea: 200 mg single dose
- Skin and skin structure infections: 400 mg every 12 hours for 7-14 days
- Acute maxillary sinusitis: 200 mg every 12 hours for 10 days
- Uncomplicated urinary tract infection: 100 mg every 12 hours for 7 days
Cefpodoxime must be administered with food to enhance absorption, as bioavailability is significantly reduced in the fasted state 1.
Pediatric Dosing
For children aged 2 months to 12 years, cefpodoxime is dosed at 10 mg/kg/day divided into two doses (maximum 400 mg/day) for most infections 2. The American Academy of Pediatrics specifically recommends this regimen for urinary tract infections in febrile infants and children 2-24 months 2.
For pediatric patients, the oral suspension formulation achieves higher concentrations than tablets due to superior absorption characteristics, allowing coverage of pathogens with MICs up to 1.0 mg/L 3.
Renal Impairment Dosing
For patients with severe renal impairment (creatinine clearance <30 mL/min), reduce the dosing interval to every 24 hours rather than every 12 hours 1. The milligram dose per administration should remain unchanged to maintain concentration-dependent bactericidal activity 4.
Specific adjustments based on renal function 1, 4:
- CrCl 50-80 mL/min (mild impairment): No adjustment needed; half-life increases to 3.5 hours
- CrCl 30-49 mL/min (moderate impairment): Administer every 24 hours; half-life increases to 5.9 hours
- CrCl 5-29 mL/min (severe impairment): Administer every 24 hours; half-life increases to 9.8 hours
- Hemodialysis patients: Dose 3 times per week after dialysis, as approximately 23% of the drug is removed during a standard 3-hour hemodialysis session 1, 4
The pharmacokinetic rationale is that cefpodoxime clearance correlates directly with creatinine clearance (CLP/F = 1.9 × CrCl + 18.4), and extending the dosing interval maintains similar AUC values to patients with normal renal function 4.
Special Populations
Elderly patients do not require dose adjustment unless they have diminished renal function 1, 5. In healthy geriatric subjects, the half-life averages 4.2 hours versus 3.3 hours in younger subjects, but other pharmacokinetic parameters remain unchanged 1.
Patients with cirrhosis require no dose adjustment, as hepatic impairment does not significantly alter cefpodoxime pharmacokinetics 1.
Important Clinical Considerations
The dose-normalized Cmax and AUC decrease by up to 32% with increasing doses due to saturable absorption, meaning higher doses are less efficiently absorbed 1. This non-linear pharmacokinetic profile should be considered when escalating doses.
Cefpodoxime achieves therapeutic concentrations in multiple tissue compartments: tonsil tissue (0.24 mcg/g at 4 hours), lung tissue (0.63 mcg/g at 3 hours), and skin blister fluid (1.6-2.8 mcg/mL), with concentrations exceeding MIC90 values for common pathogens for 7-12 hours after dosing 1.
A critical caveat: Adequate CSF penetration data are not available, so cefpodoxime should not be used for CNS infections 1.